AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Discover effective ways to increase your savings rate, helping you reach your financial goals faster.
22,326 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Turning Point Brands stock has fallen today even after a strong quarterly report. This article explains what happened...
With American Express set to report on July 24, analysts say a durable franchise, disciplined capital returns, and a ...
Opal Fuels closed 2025 with growing RNG-based fueling capacity and a clearer path to profitability. This article brea...
Astera Labs stands at an inflection point: rapid AI demand could lift the stock, but margin pressures and a premium v...
This week brought a notable rise for Corcept Therapeutics as investors reacted to a major catalyst. Learn what drove ...
This article dives into EverCommerce (evcm) 2026 earnings, unpacking Q1 results, growth drivers, and the implications...
LifeStance Health Group stunned the market with a beat-and-raise quarter, sending its stock up roughly 20%. This deep...
Could Amazon pull ahead of the broader market? This article builds a disciplined case for why Amazon might outperform...
AMD sits near a pivotal $420 level as first-quarter results underscore strong data-center demand and a bold AI-driven...
Investors study the math behind replacing a $75,000 salary with monthly dividend ETFs, weighing yield, risk, and long...
This deep dive breaks down NCDLs Q1 2026 performance, translates what the ncdl 2026 earnings call hinted at, and show...